Chris Schott
Stock Analyst at JP Morgan
(1.05)
# 2045
Out of 5,356 analysts
131
Total ratings
46.91%
Success rate
-1.99%
Average return
Main Sectors:
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
TEVA Teva Pharmaceutical ... | Upgrades: Overweight | 21 23 | 17.21 | 33.64% | 10 | May 12, 2025 | |
BIIB Biogen | Maintains: Neutral | 185 175 | 130.4 | 34.2% | 4 | May 5, 2025 | |
REGN Regeneron Pharmaceut... | Maintains: Overweight | 1100 1000 | 482.56 | 107.23% | 6 | Mar 31, 2025 | |
GILD Gilead Sciences | Maintains: Overweight | 120 130 | 110.46 | 17.69% | 6 | Mar 27, 2025 | |
AMRX Amneal Pharmaceutica... | Upgrades: Overweight | 9 12 | 7.17 | 67.36% | 2 | Feb 24, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 210 200 | 187.31 | 6.77% | 2 | Nov 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 630 575 | 522.08 | 10.14% | 7 | Oct 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 225 230 | 168.58 | 36.43% | 2 | Oct 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1050 1100 | 764.43 | 43.9% | 19 | Sep 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 20 | 9.21 | 117.16% | 2 | Sep 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 41 | 25.97 | 57.87% | 8 | Feb 28, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 42 | 33.76 | 24.41% | 4 | Feb 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 270 | 287.18 | -5.98% | 1 | Oct 20, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 36 34 | 23.1 | 47.19% | 7 | Oct 16, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 120 125 | 77.59 | 61.1% | 6 | Feb 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 14 | 8.46 | 65.48% | 2 | Nov 15, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 11 | 0.81 | 1258.02% | 4 | Nov 14, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Nov 14, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 24 20 | 13.43 | 48.92% | 3 | Oct 17, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 175 150 | n/a | n/a | 3 | Oct 17, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Jul 29, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 74 78 | 47.8 | 63.18% | 4 | Oct 16, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 110 | n/a | n/a | 1 | Sep 9, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 700 950 | 4.11 | 23014.36% | 4 | May 27, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 5 | May 19, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 19, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 13, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 9 | n/a | n/a | 6 | May 13, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 45 50 | 26.75 | 86.92% | 3 | Nov 2, 2018 |